Welcome to our dedicated page for Nanoviricides news (Ticker: NNVC), a resource for investors and traders seeking the latest updates and insights on Nanoviricides stock.
NanoViricides, Inc. (NNVC) generates frequent news as a clinical stage biotechnology company focused on nanomedicine-based antiviral drug candidates. Its updates center on the development and regulatory progress of NV-387, a broad-spectrum antiviral that the company states is designed to mimic host cell attachment receptors such as sulfated proteoglycans, aiming to trap and neutralize a wide range of human pathogenic viruses.
News coverage for NanoViricides often highlights clinical and regulatory milestones. Recent announcements include approval by the regulatory agency ACOREP in the Democratic Republic of Congo to start a Phase II clinical trial of NV-387 for MPox, ongoing work toward a Phase II trial for viral acute and severe acute respiratory infections (viral ARI/SARI), and preparations for orphan drug designation applications for MPox, Smallpox, and Measles. The company also reports on its Phase I safety results for NV-387 and describes its efforts to advance NV-387 into Phase II human clinical trials.
Investors and observers following NNVC news can expect detailed discussions of preclinical and clinical data in animal models and early human studies, including comparisons of NV-387 to existing antivirals such as oseltamivir, baloxavir, peramivir, remdesivir, and tecovirimat. Press releases frequently address emerging viral threats, such as influenza A/H3N2 variants, H5N1 bird flu, MPox clades, coronaviruses, RSV, and Measles, and position NV-387 within these contexts.
NanoViricides also issues news on financing events, such as registered direct offerings and concurrent private placements, which support its research and development plans. Additional coverage includes presentations at investor and partnering conferences, shareholder meeting announcements, and commentary from company leadership on the potential role of nanoviricide technology in pandemic preparedness and bioterrorism response. Bookmark this page to review ongoing NNVC news as the company reports new data, regulatory interactions, and corporate developments.
NanoViricides (NYSE:NNVC) will hold its Annual Shareholders Meeting on November 8, 2025 at 10:00 am at Hampton Inn & Suites Stamford, CT. Management will review progress toward clinical development, including completion of the Clinical Trial Application and plans to initiate a Phase II trial of NV-387 for MPox in the Democratic Republic of Congo. NV-387 completed a Phase I trial with a described safety and tolerability profile and showed efficacy in animal orthopoxvirus models versus tecovirimat.
The release also summarises MPox risks (recent US Clade I cases, case fatality ranges) and contrasts NV-387 with existing countermeasures and their limitations.
NanoViricides (NYSE American: NNVC) will present at the Spartan Capital Investor Conference in New York City on November 3, 2025 at 09:45am ET. Anil R. Diwan, PhD, President and Executive Chairman, will provide an update on the company, its drug pipeline and nanoviricide platform technologies available for licensing.
Key disclosed items include: NV-387 in Phase II (planned MPox trial in Democratic Republic of Congo) and development for RSV, influenza, COVID/Long COVID, and other respiratory indications; clinical-ready NV-HHV-1 (pan-herpesvirus) and NV-HIV-1; and platform capabilities for drug encapsulation, oral delivery, and targeted "zip-code" delivery. The release reiterates forward-looking risks and uncertainty about timelines, regulatory approvals, and development outcomes.
NanoViricides (NYSE American: NNVC) CEO Dr Anil Diwan told Proactive (Oct 29, 2025) that lead drug NV-387 showed potent anti-measles activity in cell culture and a humanized animal model and protected lung tissue.
In a lethal measles model, NV-387 extended survival by 130% (from 7.4 days to 17 days). NV-387 completed Phase I with no reportable adverse events and is formulated as oral gummies. The company said it can support emergency use or physician-initiated INDs and is advancing NV-387 into Phase II for MPox.
NanoViricides (NYSE American: NNVC) will present at PODD 2025 in Boston on October 27, 2025 at 03:00 pm; Anil R. Diwan, PhD, will update the company, its drug pipeline, and licensing opportunities.
The company says lead candidate NV-387 is moving into Phase II for MPox in the Democratic Republic of Congo and a separate Phase II for respiratory ARI/SARI is being planned. NV-387 reportedly showed complete cure in an RSV animal study and activity versus Influenza A, coronaviruses, measles, and orthopox models. The company cites a total addressable market in excess of $10 billion. NanoViricides also describes clinical-ready candidates NV-HHV-1 and NV-HIV-1 and platform capabilities for oral delivery and targeted encapsulation.
NanoViricides (NYSE American: NNVC) announced that its lead candidate NV-387 showed strong antiviral activity against Measles in cell culture and a humanized lethal mouse model, increasing median survival to 17 days from 7.4 days (a 130% increase).
NV-387 treatment correlated with slower disease progression, reduced lung plaques, and lower lung infiltration by lymphocytes and neutrophils. NV-387 completed Phase I with no reportable adverse events and is available as an oral gummy formulation. The company said Measles-specific development is not cost-effective and intends to seek non-dilutive grants while advancing NV-387 for multiple respiratory viruses.
NanoViricides (NYSE American: NNVC) announced that its lead drug NV-387 showed strong activity against measles in a humanized animal model and can be made available now for emergency use via Physician Investigator Initiated INDs.
Key data: survival increased to 17 days vs 7.4 days (≈130% increase) in treated animals, dose-dependent survival, and no signs of toxicity. NV-387 completed a Phase I study in healthy subjects with no reported adverse events. The drug is manufactured under GMP in the USA and is formulated as oral gummies for easy administration.
NanoViricides (NYSE:NNVC) outlined a dual-track clinical strategy for its broad‑spectrum polymeric micelle antiviral NV-387, targeting MPox and acute respiratory viruses (influenza, coronaviruses, RSV).
Key disclosed facts: NV-387 completed a Phase 1 safety/tolerability study in 2023; an MPox Phase 2 trial has ethics approval in Congo and could begin by late CY2025–early CY2026; an adaptive respiratory “basket” Phase 2 trial in India is targeted for winter 2026 with possible US follow-ups in 2027. Management cited independent market estimates of $2.6bn for RSV and $4.6bn for influenza.
NanoViricides (NYSE:NNVC) has filed its Annual Report for fiscal year 2025, highlighting significant progress with its lead drug candidate NV-387. The broad-spectrum antiviral has advanced to Phase II clinical trials, showing promise as a potential revolutionary treatment for respiratory viral infections with a projected market size exceeding $20 billion.
The company reported cash and equivalents of $1.67 million as of June 30, 2025, with $6.83 million in net property assets. Financial challenges persist with substantial doubt about continuing operations, though the company secured a $3 million credit line and raised additional funds through ATM offerings.
Key developments include plans for Phase II MPox trials in Africa, potential US Strategic National Stockpile acquisition worth ~$1 billion for Smallpox treatment, and multiple upcoming regulatory milestones. NV-387 has demonstrated superior effectiveness compared to existing treatments in various viral infection models.
NanoViricides (NYSE American:NNVC) will present at the Life Science Executive Partnering Congress in Boston on September 17, 2025. The company's President, Dr. Anil R. Diwan, will showcase their revolutionary antiviral drug pipeline, highlighting their lead candidate NV-387.
NV-387 is an ultra-broad-spectrum antiviral designed to combat multiple respiratory viruses including RSV, Influenza A, and Coronaviruses. The drug is advancing towards Phase II trials for MPOX treatment and has shown effectiveness against multiple viruses in animal studies. The company estimates the overall market size for NV-387 indications to exceed $10 billion.
Additionally, NanoViricides has developed NV-HHV-1 for herpesvirus treatment and NV-HIV-1 for HIV treatment, both showing promising results in preclinical studies.
NanoViricides (NYSE:NNVC) will present at the LSX World Congress in Boston on September 17, 2025, where Dr. Anil R. Diwan will provide updates on the company's drug pipeline and platform technologies. The company's lead candidate, NV-387, is an ultra-broad-spectrum antiviral designed to combat multiple respiratory viruses and is advancing towards Phase II trials for MPOX treatment.
NV-387 has demonstrated effectiveness against the "tripledemic" respiratory viruses (RSV, Influenza A, Coronaviruses) and shown promise in treating Smallpox, MPox, and Measles. The drug's potential market size is estimated at over $10 billion, with additional opportunities through Priority Review Vouchers worth $150-350 million each and possible government contracts for bioterrorism defense.